CureVac N.V.
CureVac N.V. (CVAC): 7 pipeline candidates · ~29 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
28.6 months
D/E 0.17 · 0% dilution
Lead: Phase 1
7 candidates
N/A
N/A
A transparent, data-derived signal for CureVac N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.0B
Cash
$392.7M
Quarterly Burn
$42.1M
Runway
28.6 mo
Revenue
$1.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| CV09050101 mRNA vaccine 100 μg | Phase 1 |
| CV09050101 mRNA vaccine 12 μg | Phase 1 |
| CV09050101 mRNA vaccine 25 μg | Phase 1 |
| CV09050101 mRNA vaccine 50 μg | Phase 1 |
| CV09050101 mRNA vaccine 6 μg | Phase 1 |
| CV09050101 mRNA vaccine RDE 100 μg | Phase 1 |
| cv09070101 mrna vaccine | Phase 1 |
Frequently asked questions
How many drug candidates are in CureVac N.V.'s pipeline?
CureVac N.V. (CVAC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CureVac N.V.'s lead drug candidate?
CureVac N.V.'s most advanced tracked candidate is CV09050101 mRNA vaccine 100 μg (Phase 1) for Squamous NSCLC.
What is CureVac N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CureVac N.V. has approximately 28.6 months of cash runway.
What is CureVac N.V.'s market capitalization?
CureVac N.V.'s market capitalization is approximately $1.0B.
Get the full picture on CureVac N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.